Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies

被引：0
|
作者：
Sharon Walmsley
Don E. Smith
Miguel Górgolas
Pedro E. Cahn
Thomas Lutz
Karine Lacombe
Princy N. Kumar
Brian Wynne
Richard Grove
Gilda Bontempo
Riya Moodley
Chinyere Okoli
Michelle Kisare
Bryn Jones
Andrew Clark
Mounir Ait-Khaled
机构：
[1] University Health Network,
[2] Albion Centre,undefined
[3] Fundación Jiménez Díaz,undefined
[4] Universidad Autónoma de Madrid,undefined
[5] Fundación Huésped,undefined
[6] Infektiologikum,undefined
[7] Hôpital Saint-Antoine,undefined
[8] Georgetown University Medical Center,undefined
[9] ViiV Healthcare,undefined
[10] GSK,undefined
[11] ViiV Healthcare,undefined
[12] ViiV Healthcare,undefined
来源：
AIDS Research and Therapy | / 21卷
关键词：
Aging; Comorbidity; DTG/3TC; HIV-1; Polypharmacy; Single-tablet regimen; Suppressed switch;  ≥ 50 years;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [31] Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study
    Spinner, Christoph D.
    Kummerle, Tim
    Schneider, Jochen
    Cordes, Christiane
    Heiken, Hans
    Stellbrink, Hans-Jurgen
    Krznaric, Ivanka
    Scholten, Stephan
    Jensen, Bjorn
    Wyen, Christoph
    Viehweger, Marin
    Lehmann, Clara
    Sprinzl, Martin
    Stoehr, Albrecht
    Bickel, Markus
    Jessen, Heiko
    Obst, Wilfried
    Spornraft-Ragaller, Petra
    Khaykin, Pavel
    Wolf, Eva
    Boesecke, Christoph
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (09):
  • [32] Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older
    Stellbrink, H-J
    Post, F. A.
    Podzamczer, D.
    Arribas, J.
    Cua, E.
    Molina, J-M
    Orkin, C.
    Rockstroh, J. K.
    Carter, C.
    Liu, Y-P
    Zhong, L.
    Das, M.
    Temme, L.
    Waters, L.
    HIV MEDICINE, 2019, 20 : 138 - 138
  • [33] The effects of switching from dolutegravir/abacavir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study
    Rossetti, B.
    Ferrara, M.
    Taramasso, L.
    Bai, F.
    Lombardi, F.
    Ciccarelli, N.
    Durante, M.
    Alladio, F.
    Rancan, I.
    Montagnani, F.
    Di Biagio, A.
    Monforte, A. d'Arminio
    Zazzi, M.
    Fabbiani, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 161 - 162
  • [34] Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3-or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
    Llibre, Josep M.
    Brites, Carlos
    Cheng, Chien-Yu
    Osiyemi, Olayemi
    Galera, Carlos
    Hocqueloux, Laurent
    Maggiolo, Franco
    Degen, Olaf
    Taylor, Stephen
    Blair, Elizabeth
    Man, Choy
    Wynne, Brian
    Oyee, James
    Underwood, Mark
    Curtis, Lloyd
    Bontempo, Gilda
    van Wyk, Jean
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (04) : 720 - 729
  • [35] Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study
    Ait-Khaled, Mounir
    Oyee, James
    Ooi, Adrian Yit Reen
    Wynne, Brian
    Maldonado, Andres
    Jones, Bryn
    Wang, Tao
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (05):
  • [36] Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
    Troya, Jesus
    Ryan, Pablo
    Ribera, Esteban
    Podzamczer, Daniel
    Hontanon, Victor
    Alberto Terron, Jose
    Boix, Vicente
    Moreno, Santiago
    Barrufee, Pilar
    Castano, Manuel
    Carrero, Ana
    Jose Galindo, Maria
    Suarez-Lozano, Ignacio
    Knobel, Hernando
    Raffo, Miguel
    Solis, Javier
    Yllescas, Maria
    Esteban, Herminia
    Gonzalez-Garcia, Juan
    Berenguer, Juan
    Imaz, Arkaitz
    PLOS ONE, 2016, 11 (10):
  • [37] Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice
    Baldin, Gianmaria
    Ciccullo, Arturo
    Borghetti, Alberto
    Di Giambenedetto, Simona
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (05) : 1461 - 1463
  • [38] Efficacy and safety of dolutegravir in treatment-naive people living with HIV-1 stratified by age: meta-analysis of 48-week results from ARIA, FLAMINGO, SINGLE, and SPRING-2
    Spinelli, F.
    Prakash, M.
    Slater, J.
    van der Kolk, M.
    Bassani, N.
    Grove, R.
    Wynne, B.
    van Wyk, J.
    Clark, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 23 - 23
  • [39] Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study
    Kumar, Princy
    Clarke, Amanda E.
    Jonsson-Oldenbuettel, Celia
    Deltoro, Miguel Garcia
    Di Giambenedetto, Simona
    Brites, Carlos
    Hocqueloux, Laurent
    Lu, Po-Liang
    Oyee, James
    Oglesby, Alan
    Wynne, Brian
    Jones, Bryn
    Evitt, Lee A.
    Fox, Dainielle
    Kisare, Michelle
    Priest, Julie
    AIDS AND BEHAVIOR, 2024, : 235 - 245
  • [40] Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
    Llibre, Josep M.
    Cahn, Pedro E.
    Lo, Janet
    Barber, Tristan J.
    Mussini, Cristina
    van Welzen, Berend J.
    Hernandez, Beatriz
    Donovan, Cynthia
    Kisare, Michelle
    Sithamparanathan, Myooran
    van Wyk, Jean
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (04):
12345